NASDAQ:XENE
Xenon Pharmaceuticals Inc. Stock News
$43.00
+0.510 (+1.20%)
At Close: May 02, 2024
Xenon Pharmaceuticals to Present at the Stifel 2023 CNS Days
04:01pm, Wednesday, 22'nd Mar 2023
BURNABY, British Columbia, March 22, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at
Xenon Pharmaceuticals Inc. (XENE) Q4 2022 Earnings Call Transcript
10:10pm, Wednesday, 01'st Mar 2023
Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Sherry Aulin - CFO Ian Mortimer - President and CEO Chris Kenney - CMO Chris Vo
Xenon Pharmaceuticals (XENE) Reports Q4 Loss, Lags Revenue Estimates
06:48pm, Wednesday, 01'st Mar 2023
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 1.72% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
BURNABY, British Columbia, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its fourth quarter
Xenon Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
04:01pm, Wednesday, 04'th Jan 2023
BURNABY, British Columbia, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at t
Xenon Pharmaceuticals: Momentum Still Accelerating, Rate Buy (Technical Analysis)
06:30am, Friday, 23'rd Dec 2022
Xenon Pharmaceuticals is a long-term compounder that's survived the last 5 years of trade as a high-Sharpe, low-vol play for the equity risk budget. With recent price action, we reviewed our position
Xenon Pharmaceuticals to Present at the Bank of America Securities Biotech SMID Cap Conference 2022
04:01pm, Wednesday, 30'th Nov 2022
BURNABY, British Columbia, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate i
Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
04:30pm, Wednesday, 09'th Nov 2022
BURNABY, British Columbia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Ian Mortimer, Xenon's Preside
Why Emergent Bio Is Leading A Biotech Bloodbath — With Xenon Pharma Trailing
10:18am, Wednesday, 09'th Nov 2022
Emergent BioSolutions led a decline for biotech stocks on Wednesday as EBS stock tumbled on declining sales and a delayed contract. The post Why Emergent Bio Is Leading A Biotech Bloodbath — With Xe
Xenon Pharmaceuticals Inc. (XENE) Q3 2022 Earnings Call Transcript
08:50pm, Tuesday, 08'th Nov 2022
Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q3 2022 Results Conference Call November 8, 2022 4:30 PM ET Company Participants Sherry Aulin - Chief Financial Officer Ian Mortimer - President and Chief Exe
Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Misses Revenue Estimates
06:48pm, Tuesday, 08'th Nov 2022
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -9.62% and 97.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the sto
Hurry! 7 Pitiful Nasdaq Stocks to Sell Before 2022 Ends.
08:25pm, Tuesday, 01'st Nov 2022
With the Fed signaling oversized rate hikes for longer is the likely trajectory moving forward, it is understandable why investors are looking for stocks to sell rather than stocks to buy. Consumer sp
BURNABY, British Columbia, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2
Polarean Imaging says US FDA requests additional information from manufacturing partner of its xenon-129 gas blend drug
04:08am, Thursday, 22'nd Sep 2022
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has announced that the US Food and Drug Administration (FDA) has requested additional information from the manufacturing partner for the company's xenon-1
Xenon Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference
04:01pm, Thursday, 01'st Sep 2022
BURNABY, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate
